Daiwa Securities Group’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-230
| Closed | -$17K | – | 1382 |
|
|
2025
Q4 | $17K | Sell |
230
-20
| -8% | -$1.45K | ﹤0.01% | 1162 |
|
|
2025
Q3 | $15K | Sell |
250
-5,035
| -95% | -$262K | ﹤0.01% | 1142 |
|
|
2025
Q2 | $258K | Buy |
5,285
+5,030
| +1,973% | +$239K | ﹤0.01% | 930 |
|
|
2025
Q1 | $13K | Hold |
255
| – | – | ﹤0.01% | 1085 |
|
|
2024
Q4 | $12K | Sell |
255
-34
| -12% | -$1.46K | ﹤0.01% | 1110 |
|
|
2024
Q3 | $11K | Hold |
289
| – | – | ﹤0.01% | 1125 |
|
|
2024
Q2 | $9K | Hold |
289
| – | – | ﹤0.01% | 1169 |
|
|
2024
Q1 | $8K | Hold |
289
| – | – | ﹤0.01% | 1180 |
|
|
2023
Q4 | $8K | Hold |
289
| – | – | ﹤0.01% | 1181 |
|
|
2023
Q3 | $6K | Hold |
289
| – | – | ﹤0.01% | 1144 |
|
|
2023
Q2 | $12K | Hold |
289
| – | – | ﹤0.01% | 1133 |
|
|
2023
Q1 | $14K | Hold |
289
| – | – | ﹤0.01% | 1088 |
|
|
2022
Q4 | $11K | Buy |
289
+23
| +9% | +$956 | ﹤0.01% | 1111 |
|
|
2022
Q3 | $13K | Hold |
266
| – | – | ﹤0.01% | 1118 |
|
|
2022
Q2 | $11K | Buy |
266
+60
| +29% | +$2.1K | ﹤0.01% | 1140 |
|
|
2022
Q1 | $8K | Hold |
206
| – | – | ﹤0.01% | 1151 |
|
|
2021
Q4 | $8K | Sell |
206
-36
| -15% | -$1.38K | ﹤0.01% | 1165 |
|
|
2021
Q3 | $9K | Buy |
242
+103
| +74% | +$4.23K | ﹤0.01% | 1151 |
|
|
2021
Q2 | $6K | Hold |
139
| – | – | ﹤0.01% | 1065 |
|
|
2021
Q1 | $7K | Buy |
139
+11
| +9% | +$653 | ﹤0.01% | 1060 |
|
|
2020
Q4 | $8K | Sell |
128
-230
| -64% | -$13.6K | ﹤0.01% | 1029 |
|
|
2020
Q3 | $17K | Buy |
358
+10
| +3% | +$492 | ﹤0.01% | 1005 |
|
|
2020
Q2 | $16K | Hold |
348
| – | – | ﹤0.01% | 1039 |
|
|
2020
Q1 | $16K | Hold |
348
| – | – | ﹤0.01% | 1024 |
|
|
2019
Q4 | $17K | Sell |
348
-17
| -5% | -$722 | ﹤0.01% | 1026 |
|
|
2019
Q3 | $12K | Hold |
365
| – | – | ﹤0.01% | 1025 |
|
|
2019
Q2 | $16K | Hold |
365
| – | – | ﹤0.01% | 1028 |
|
|
2019
Q1 | $14K | Buy |
365
+136
| +59% | +$4.57K | ﹤0.01% | 1012 |
|
|
2018
Q4 | $8K | Hold |
229
| – | – | ﹤0.01% | 1012 |
|
|
2018
Q3 | $11K | Hold |
229
| – | – | ﹤0.01% | 1033 |
|
|
2018
Q2 | $8K | Hold |
229
| – | – | ﹤0.01% | 1069 |
|
|
2018
Q1 | $6K | Buy |
+229
| New | +$5.8K | ﹤0.01% | 1063 |
|
Other funds holding PTCT
RI
VPM
VCM
AC
Daiwa Securities Group's PTCT Position: Q1 2026 in Review
Daiwa Securities Group sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 230 shares — an estimated $17K sold.
Daiwa Securities Group first reported a position in PTCT in Q1 2018 and held it in 32 quarters. The position peaked at $258K in Q2 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.
- Daiwa Securities Group reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 230 PTC Therapeutics shares in Q1 2026, an estimated $17K.
- Daiwa Securities Group first reported a position in PTC Therapeutics in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's PTC Therapeutics position peaked at $258K in Q2 2025.
- 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.